MicroRNA-217 functions as a tumour suppressor gene and correlates with cell resistance to cisplatin in lung cancer

Molecules and Cells

Volumn 37, Issue 9, 2014, Pages 664-671

  Guo, Junhua ^a   Feng, Zhijun ^a   Huang, Zhi’ang ^a   Wang, Hongyan ^a   Lu, Wujie ^a  

^a HENAN UNIVERSITY   (China)

Author keywords

Cisplatin; KRAS; Lung cancer; miR 217; Tumour suppressor

Indexed keywords

CISPLATIN; K RAS PROTEIN; MICRORNA; MICRORNA 217; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; MIRN217 MICRORNA, HUMAN; ONCOPROTEIN; RAS PROTEIN;

A549 CELL LINE; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL MIGRATION; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; LUNG CANCER; LUNG CANCER CELL LINE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; SOFTWARE; SPC A 1 CELL LINE; TUMOR INVASION; TUMOR SUPPRESSOR GENE; UPREGULATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CASE CONTROL STUDY; CELL MOTION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG NEOPLASMS; MALE; MICE, INBRED BALB C; MICRORNAS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84934277207     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.14348/molcells.2014.0121     Document Type: Article

References (30)

1. Ambs, S., Prueitt, R.L., Yi, M., Hudson, R.S., Howe, T.M., Petrocca, F., Wallace, T.A., Liu, C.G., Volinia, S., Calin, G.A., et al. (2008). Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 68, 6162-6170.
2. Bian, H.B., Pan, X., Yang, J.S., Wang, Z.X., and De, W. (2011). Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J. Exp. Clin. Cancer Res. 30, 20.
3. Cimmino, A., Calin, G.A., Fabbri, M., Iorio, M.V., Ferracin, M., Shimizu, M., Wojcik, S.E., Aqeilan, R.I., Zupo, S., Dono, M., et al. (2005). miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA 102, 13944-13949.
4. Deng, S., Calin, G.A., Croce, C.M., Coukos, G., and Zhang, L. (2008). Mechanisms of microRNA deregulation in human cancer. Cell Cycle 7, 2643-2646.
5. Engels, B.M., and Hutvagner, G. (2006). Principles and effects of microRNA-mediated post-transcriptional gene regulation. Oncogene 25, 6163-6169.
6. Esteller, M. (2011). Non-coding RNAs in human disease. Nat. Rev. Genet. 12, 861-874.
7. Garzon, R., Calin, G.A., and Croce, C.M. (2009). MicroRNAs in cancer. Annu. Rev. Med. 60, 167-179.
8. Giovannetti, E., Funel, N., Peters, G.J., Del Chiaro, M., Erozenci, L.A., Vasile, E., Leon, L.G., Pollina, L.E., Groen, A., Falcone, A., et al. (2010). MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 70, 4528-4538.
9. Guttilla, I.K., and White, B.A. (2009). Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J. Biol. Chem. 284, 23204-23216.
10. Inomata, M., Tagawa, H., Guo, Y.M., Kameoka, Y., Takahashi, N., and Sawada, K. (2009). MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood 113, 396-402.
11. Iorio, M.V., Visone, R., Di Leva, G., Donati, V., Petrocca, F., Casalini, P., Taccioli, C., Volinia, S., Liu, C.G., Alder, H., et al. (2007). Mi croRNA signatures in human ovarian cancer. Cancer Res. 67, 8699-8707.
12. Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010). Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300.
13. Johnson, S.M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K.L., Brown, D., and Slack, F.J. (2005). RAS is regulated by the let-7 microRNA family. Cell 120, 635-647.
14. Kato, M., Putta, S., Wang, M., Yuan, H., Lanting, L., Nair, I., Gunn, A., Nakagawa, Y., Shimano, H., Todorov, I., et al. (2009). TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat. Cell Biol. 11, 881-889.
15. Ma, J., Dong, C., and Ji, C. (2010). MicroRNA and drug resistance. Cancer Gene Ther. 17, 523-531.
16. Menghini, R., Casagrande, V., Cardellini, M., Martelli, E., Terrinoni, A., Amati, F., Vasa-Nicotera, M., Ippoliti, A., Novelli, G., Melino, G., et al. (2009). MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. Circulation 120, 1524-1532.
17. Pasquinelli, A.E. (2012). MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat. Rev. Genet. 13, 271-282.
18. Qi, L., Bart, J., Tan, L.P., Platteel, I., Sluis, T., Huitema, S., Harms, G., Fu, L., Hollema, H., and Berg, A. (2009). Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer 9, 163.
19. Schepeler, T., Reinert, J.T., Ostenfeld, M.S., Christensen, L.L., Silahtaroglu, A.N., Dyrskjot, L., Wiuf, C., Sorensen, F.J., Kruhoffer, M., Laurberg, S., et al. (2008). Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res. 68, 6416-6424.
20. Slack, F.J., and Weidhaas, J.B. (2008). MicroRNA in cancer prognosis. N Engl. J. Med. 359, 2720-2722.
21. Sorrentino, A., Liu, C.G., Addario, A., Peschle, C., Scambia, G., and Ferlini, C. (2008). Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol. Oncol. 111, 478-486.
22. Su, J., Wang, Q., Liu, Y., and Zhong, M. (2014). miR-217 inhibits invasion of hepatocellular carcinoma cells through direct suppression of E2F3. Mol. Cell. Biochem.392, 289-296.
23. Tomari, Y., and Zamore, P.D. (2005). Perspective: machines for RNAi. Genes Dev. 19, 517-529.
24. Wang, R., Wang, Z.X., Yang, J.S., Pan, X., De, W., and Chen, L.B. (2011). MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene 30, 2644-2658.
25. Yu, S., Lu, Z., Liu, C., Meng, Y., Ma, Y., Zhao, W., Liu, J., Yu, J., and Chen, J. (2010a). miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res. 70, 6015-6025.
26. Yu, Z.W., Zhong, L.P., Ji, T., Zhang, P., Chen, W.T., and Zhang, C.P. (2010b). MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol. 46, 317-322.
27. Zhang, B., Pan, X., Cobb, G.P., and Anderson, T.A. (2007). microRNAs as oncogenes and tumor suppressors. Dev. Biol.302, 1-12.
28. Zhang, T., Wang, Q., Zhao, D., Cui, Y., Cao, B., Guo, L., and Lu, S.H. (2011). The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Clin. Sci. 121, 437-447.
29. Zhang, H.S., Wu, T.C., Sang, W.W., and Ruan, Z. (2012). MiR-217 is involved in Tat-induced HIV-1 long terminal repeat (LTR) transactivation by down-regulation of SIRT1. Biochim. Biophys. Acta 1823, 1017-1023.
30. Zhao, W.G., Yu, S.N., Lu, Z.H., Ma, Y.H., Gu, Y.M., and Chen, J. (2010). The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. Carcinogenesis 31, 1726-1733.